Literature DB >> 2278

The structure of the covalent adduct formed by the interaction of 3-dimethylamino-1-propyne and the flavine of mitochondrial amine oxidase.

A L Maycock, R H Abeles, J I Salach, T P Singer.   

Abstract

3-Dimethylamino-1-propyne irreversibly inactivates mitochondrial monoamine oxidase from bovine liver. The inactivation results in the loss of absorption in the 450-500-nm region of the flavine spectrum and a concomitant increase in absorbance at 410 nm. For the enzyme-bound adduct epsilon410 = 28000. The spectral properties of the adduct of the liver enzyme with 3-dimethylamino-1-propyne are similar to those observed when the pig kidney enzyme is inactivated with pargyline (Chuang et al. (1974), J. Biol. Chem. 249, 2381). From a proteolytic digest of the enzyme inactivated with labeled inhibitor a flavine peptide has been isolated which contains 1 mol of inactivator/mol of flavine. The chemical and spectral properties of the adduct are those of compounds containing the structure --N--CH==CH--CH==N+ less than. It was concluded that the flavine-inhibtor adduct is a N-5 substituted dihydroflavine and its structure has been determined.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 2278     DOI: 10.1021/bi00646a018

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor.

Authors:  Matic Pavlin; Janez Mavri; Matej Repič; Robert Vianello
Journal:  J Neural Transm (Vienna)       Date:  2013-04-02       Impact factor: 3.575

Review 2.  Kinetics, mechanism, and inhibition of monoamine oxidase.

Authors:  Rona R Ramsay; Alen Albreht
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

3.  Low monoamine oxidase B in peripheral organs in smokers.

Authors:  Joanna S Fowler; Jean Logan; Gene-Jack Wang; Nora D Volkow; Frank Telang; Wei Zhu; Dinko Franceschi; Naomi Pappas; Richard Ferrieri; Colleen Shea; Victor Garza; Youwen Xu; David Schlyer; S John Gatley; Yu-Shin Ding; David Alexoff; Donald Warner; Noelwah Netusil; Pauline Carter; Millard Jayne; Payton King; Paul Vaska
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

4.  Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain.

Authors:  A L Ask; I Fagervall; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

5.  Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.

Authors:  C J Bench; G W Price; A A Lammertsma; J C Cremer; S K Luthra; D Turton; R J Dolan; R Kettler; J Dingemanse; M Da Prada
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Analysis of High-Dimensional Structure-Activity Screening Datasets Using the Optimal Bit String Tree.

Authors:  Ke Zhang; Jacqueline M Hughes-Oliver; S Stanley Young
Journal:  Technometrics       Date:  2013

7.  Inhibition of squalene epoxidase by allylamine antimycotic compounds. A comparative study of the fungal and mammalian enzymes.

Authors:  N S Ryder; M C Dupont
Journal:  Biochem J       Date:  1985-09-15       Impact factor: 3.857

8.  Mutagenic probes of the role of Ser209 on the cavity shaping loop of human monoamine oxidase A.

Authors:  Jin Wang; Johnny Harris; Darrell D Mousseau; Dale E Edmondson
Journal:  FEBS J       Date:  2009-07-23       Impact factor: 5.542

9.  Mechanistic analysis of a suicide inactivator of histone demethylase LSD1.

Authors:  Lawrence M Szewczuk; Jeffrey C Culhane; Maojun Yang; Ananya Majumdar; Hongtao Yu; Philip A Cole
Journal:  Biochemistry       Date:  2007-05-19       Impact factor: 3.162

10.  Titration of human brain monoamine oxidase -A and -B by clorgyline and L-deprenil.

Authors:  C J Fowler; L Oreland; J Marcusson; B Winblad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-04       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.